Merck KGaA Q2 Net Profit Rises, EBITDA Down; Lifts FY25 EBITDA Pre View, Cuts Sales Growth Target

Merck KGaA reported mixed second-quarter results, with net profit rising 8.3% to €655 million, yet EBITDA declined 8.5% to €1.35 billion and net sales fell 1.8% to €5.26 billion, despite 2% organic sales growth. Looking ahead, the company raised its fiscal 2025 EBITDA pre organic growth guidance to 4-8% (from 2-7%), driven by positive adjustments in Life Science and Healthcare sectors and strong cost discipline, while slightly trimming its Group organic sales growth target to 2-5%. This signals a strategic emphasis on future profitability and operational efficiency despite a more modest top-line projection.

Analysis

Merck KGaA presented mixed second-quarter results, characterized by a conflict between current performance and future guidance. While net profit grew 8.3% to €655 million, this was overshadowed by a 1.8% decline in net sales to €5.26 billion and a more significant 8.5% drop in EBITDA to €1.35 billion. The sales decline was driven entirely by a 4.2% negative foreign exchange effect, which masked a 2% organic sales increase. The key development is the company's revised fiscal 2025 guidance, which signals a strategic pivot towards profitability over pure growth. Management raised its forecast for organic EBITDA pre-growth to a range of 4% to 8%, up from 2% to 7%, citing strong cost discipline and improved outlooks for its Life Science and Healthcare segments. This upgrade comes despite a slight trimming of the group's organic sales growth target to a 2% to 5% range, indicating a clear focus on margin enhancement in the face of geopolitical uncertainties and currency headwinds.

Key Decisions for Investors

• Investors should weigh the current pressure on reported sales and EBITDA against management's increased confidence in future profitability, as demonstrated by the raised 2025 EBITDA pre-growth guidance of 4-8%.
• Monitor the company's execution on its stated 'high cost discipline' and margin performance in the Life Science and Healthcare sectors, as these are the primary drivers for the improved earnings outlook.
• Given the significant 4.2% negative FX impact on Q2 revenues, it is crucial to account for ongoing currency volatility when assessing the company's underlying organic performance and future earnings potential.